Management of Acute Hepatitis C
Section snippets
Diagnosis of acute HCV infection
An accurate diagnosis of acute HCV infection can often be elusive. The most accepted method of diagnosis is the documentation of recent (ie, in the previous 6 months) seroconversion of HCV antibody associated with detectable HCV RNA and elevated liver enzymes. These stringent diagnostic criteria can only be fulfilled during the follow-up of a documented needle-stick exposure or by prospective surveillance of high-risk groups, such as injection drug users. When these criteria are not met,
Treatment of acute HCV infection
Unlike the treatment of chronic HCV infection, the published studies show considerable heterogeneity with regard to trial design (randomized vs nonrandomized), inclusion criteria (type of exposure and methods of diagnosis), patient characteristics, treatment introduction relative to exposure date or onset of symptoms, and treatment modality (varying schedules of interferon [IFN] and ribavirin doses and durations). This makes it harder to make firm recommendations or provide a specific algorithm
Optimal timing of treatment
Although treatment of acute HCV infection is highly effective, the immediate introduction of treatment is not recommended for all patients, especially those with symptomatic infection, because many of them may undergo spontaneous viral clearance. The goal of therapy is to avoid treatment in those patients who are more likely to undergo spontaneous viral clearance and treat others when treatment is likely to be most effective.
The incidence of spontaneous clearance of HCV infection is highest
Duration of treatment
The benchmark study using conventional IFN therapy demonstrated an SVR rate of 98% with 24 weeks of therapy.11 Japanese investigators suggested that a shorter course of daily IFN for 4 weeks was also highly efficacious. They demonstrated viral clearance in 87% with 4 weeks of daily IFN therapy, and reserved 24-week treatment only for the relapsing group, achieving SVR rates of 100%.14 However, the treatment regimens used in these studies have not been duplicated and with the advent of PEG-IFN,
Optimal treatment regimen
There is no consensus on a standardized treatment regimen, mainly because the studies published to date have included heterogeneous patient populations without any direct comparisons between various treatment modalities. Early Japanese studies used IFN-β, whereas the European and American studies have used IFN-α. The dose of conventional IFN used in various studies has also been variable. With the approval of the PEG-IFNs and evidence of improved efficacy in patients with chronic hepatitis C,
Treatment of HIV–co-infected or hemodialysis patients
Recent outbreaks of acute HCV infections related to sexual exposure among the MSM (men who have sex with men) populations have been reported from HIV treatment centers in London and Paris. This has prompted a few small single-center trials for the treatment of acute HCV infection among patients with prior HIV infection. Data from these trials suggest that the rate of viral clearance among the HIV co-infected population is lower than that seen in the HCV mono-infected patients. Gilleece and
Summary
The identification of acute HCV infection represents a unique window of opportunity for achieving high rates of viral clearance. A waiting period for observation of 12 weeks is recommended for patients with symptomatic hepatitis to allow for spontaneous viral clearance that can occur at high rates in this subgroup. Asymptomatic patients may be treated immediately as they are less likely to undergo spontaneous clearance. Treatment durations could vary from 24 to 48 weeks, but recent data on 12
References (29)
- et al.
When and how to treat acute hepatitis C?
J Hepatol
(2003) - et al.
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load
Hepatology
(2003) - et al.
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance
Gastroenterology
(2003) - et al.
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response
Gastroenterology
(2006) - et al.
Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance
J Hepatol
(2005) - et al.
Early versus delayed treatment of acute Hepatitis C: the German HEP-NET acute HCV-III study – A randomized controlled trial
J Hepatol
(2009) - et al.
Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C
J Hepatol
(2005) - et al.
Outcomes and treatment of acute hepatitis C virus infection in a United States population
Clin Gastroenterol Hepatol
(2006) Hepatitis C – Global prevalence (update)
Wkly Epidemiol Rec
(1999)- et al.
Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha
J Antimicrob Chemother
(2008)
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis
N Engl J Med
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
Hepatology
Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis
MMWR Morb Mortal Wkly Rep
Therapy of acute hepatitis C
Hepatology
Cited by (58)
Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy—updated guidelines: Replaces Consult Number 43, November 2017
2021, American Journal of Obstetrics and GynecologySofosbuvir plus ribavirin combination regimen boost liver functions and antioxidant profile in hepatitis C virus patients
2021, Microbial PathogenesisCitation Excerpt :Some social practices, such as sharing common shaving tools at barber shops, home diabetes testing equipment, and toothbrushes are considerable risk factors outside the health care settings [2]. About eighty percent of patients exposed to the virus through blood transfusion or un sterilized medical equipment develop a chronic infection [3] and most of them show minimal or no symptoms during the initial few decades of the infection [4]. The pathogenesis of hepatitis C virus infection returns to combination of the immune response and direct effects of the virus on the hepatocytes, including chronic inflammation, cell activation and formation of abnormal extra cellular matrix which causes inhibition of electron transport, increased production of reactive oxygen species, and decreased mitochondrial glutathione [5] which results in elevate oxidative stress in conjunction with decreased antioxidant defenses [6].
Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease
2019, Bioorganic and Medicinal Chemistry LettersA review on HCV inhibitors: Significance of non-structural polyproteins
2019, European Journal of Medicinal ChemistryCitation Excerpt :The prime concerns in the spreading the acute and chronic HCV infections is through the contact of blood products by intravenous mode of Drug Use (IDU), unsafe surgical procedures and untested body fluid transfusion. The others mode includes sharing of injectible syringes, inadequate sterilization of medical equipments and sexual communication (Fig. 2b) [10,11]. According to Centre for Disease Control and Prevention (CDC), the number new acute infections are being increasing the United States from last few years.
Acute hepatitis C from heterosexual transmission
2018, IDCasesHepatitis C in pregnancy: screening, treatment, and management
2017, American Journal of Obstetrics and Gynecology